慢性腎臓病に伴う貧血を有する日本人血液透析患者におけるGSK1278863の安全性、有効性および薬物動態を評価する研究

基本情報

NCT ID: NCT02019719
ステータス: 完了
試験のフェーズ: 第2相
試験タイプ: 介入
目標被験者数: 97
治験依頼者名: GlaxoSmithKline

概要

This study aims to characterize the relationship between dose of GSK1278863 and hemoglobin (Hgb) response in hemodialysis-dependent (HDD) subjects with anemia associated with chronic kidney disease (CKD). It is anticipated that the data generated will enable selection of the starting dose(s) and optimize dose adjustment regimen(s) for Phase 3 clinical trials. This study will consist of a screening phase of 3-9 weeks, a 4-week treatment phase and a follow-up visit approximately 4 weeks after completing treatment.

対象疾患

Anaemia

介入

GSK1278863(DRUG)

Placebo(DRUG)

依頼者（Sponsor）

グラクソ・スミスクライン株式会社(INDUSTRY)